Therapy News and Research

RSS

Neuroptix announces closing of $4 million Series C funding round

Neuroptix Corporation, a leading innovator in the early detection of Alzheimer's Disease through a non-invasive eye test, today announced that it has closed the first approximately $4 Million tranche of a Series C funding round, as the company continues clinical development of its diagnostic platform.

10 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

Civitas receives $20 million Series A financing

Civitas Therapeutics, Inc., a privately held biopharmaceutical company focused on developing transformative pulmonary delivery therapies, announced today that it has secured a $20 million Series A financing from founding investor, Longitude Capital, along with co-lead Canaan Partners. The proceeds of the financing will be primarily used to advance Civitas' lead program for treating patients with Parkinson's disease through clinical proof-of-concept.

10 Jan 2011

Research suggests novel therapeutic approach for Huntington's Disease

Hope for new ways of treating devastating neurodegenerative disorders such as Huntington's disease has been raised by a trans-Atlantic team of researchers thanks to the use of cutting-edge genetic techniques.

10 Jan 2011

LabCorp to market On-Q-ity's circulating tumor cell platform

On-Q-ity, a next-generation oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, today announced a strategic alliance with Laboratory Corporation of America Holdings® (LabCorp). LabCorp will market On-Q-ity's novel and proprietary circulating tumor cell (CTC) platform to the biopharma industry to greatly accelerate and improve the cancer drug discovery and development process.

10 Jan 2011

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

Amsterdam Molecular Therapeutics, a leader in human gene therapy, announced today that it has entered into an agreement with Institut Pasteur, Paris, France, and a group of French research institutes (together the "Consortium") to support clinical development of a novel gene therapy to treat Sanfilippo B.

10 Jan 2011

Quality of life measures most useful for clinical decision-making in trials with QOL as primary outcome

Quality of life measures tend to be most useful for clinical decision-making in trials in which quality of life is the primary outcome, according to a recent study published online January 7 in The Journal of the National Cancer Institute.

10 Jan 2011

New mechanisms of resistance to chemotherapy among leukemia patients

The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers reports today in the Jan. 4 edition of the Journal of the American Medical Association.

10 Jan 2011

FDA, EMA accept boceprevir for expedited review

Merck, known as MSD outside the United States and Canada, announced today that regulatory applications for boceprevir, Merck's investigational oral hepatitis C virus (HCV) protease inhibitor, were submitted in 2010 and have been accepted for expedited review in both the U.S. and the European Union.

10 Jan 2011

Scientists discover new anti-cancer mechanism

Scientists attached to VIB and K.U.Leuven have succeeded in decoding a potential new anti-cancer mechanism. The researchers discovered that normalizing abnormal tumor blood vessels through HRG prevents metastasis of tumor cells and enhances chemotherapy efficiency.

10 Jan 2011

Positive PK study results from ECLIPSE trial against cardiovascular disease

Omthera Pharmaceuticals, a privately-held emerging specialty pharmaceuticals company, today announced data from its ECLIPSE trial, designed to evaluate the bioavailability of Epanova™, the Company's lead compound for the treatment of very high triglycerides, in comparison to Lovaza®, the leading prescription Omega 3.

10 Jan 2011

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Inhibitex, today reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus.

10 Jan 2011

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

9 Jan 2011

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Entelos, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,853,406 entitled "Predictive Toxicology for Biological Systems" to the Company.

9 Jan 2011

Abstral transmucosal tablets receive FDA approval, may help manage pain in cancer patients

The U.S. Food and Drug Administration today approved Abstral transmucosal tablets to manage breakthrough pain for adults with cancer.

9 Jan 2011

PCPs and kidney specialists favor collaborative care for progressive chronic kidney disease

Most primary care physicians (PCPs) and kidney specialists favor collaborative care for a patient with progressive chronic kidney disease (CKD), but their preferences on how and when to collaborate differ, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). PCPs and kidney specialists need to partner more effectively to optimize care for patients with CKD.

7 Jan 2011

CORE Health Centers is now Inspire Health

On January 7th CORE Health Centers, LLC: a distinguished outpatient, multi-disciplinary, weight management treatment center in the Chicago area, officially changed its name to Inspire Health. The change to Inspire Health more accurately reflects its mission of providing effective psychological and physiological treatments for healthy weight loss and management.

7 Jan 2011

Low incentive fails to 'switch off' brain regions involved in mind-wandering among ADHD children

Brain scans of children with attention-deficit/hyperactivity disorder (ADHD) have shown for the first time why people affected by the condition sometimes have difficulty in concentrating. The study, by experts at The University of Nottingham, may explain why parents often say that their child can maintain concentration when they are doing something that interests them, but struggles with boring tasks.

7 Jan 2011

Roundup: Calif. and health reform; Conn. mental health parity; Insurance premium increases in Iowa, Fla.

Wellmark Blue Cross and Blue Shield's proposed 11 percent health insurance premium increase is excessive, two experts have concluded. The company, which insures three-quarters of Iowans who buy their own policies, already raised premiums on those plans an average of 18 percent last spring. Wellmark sparked outcries when it announced in November that it wants to raise those rates again in order to keep up with rising prices and increased use of medical care (Leys, 1/7).

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Therapy News and Research

Neuroptix announces closing of $4 million Series C funding round

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Civitas receives $20 million Series A financing

Research suggests novel therapeutic approach for Huntington's Disease

LabCorp to market On-Q-ity's circulating tumor cell platform

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

Quality of life measures most useful for clinical decision-making in trials with QOL as primary outcome

New mechanisms of resistance to chemotherapy among leukemia patients

FDA, EMA accept boceprevir for expedited review

Scientists discover new anti-cancer mechanism

Positive PK study results from ECLIPSE trial against cardiovascular disease

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Abstral transmucosal tablets receive FDA approval, may help manage pain in cancer patients

PCPs and kidney specialists favor collaborative care for progressive chronic kidney disease

CORE Health Centers is now Inspire Health

Low incentive fails to 'switch off' brain regions involved in mind-wandering among ADHD children

Roundup: Calif. and health reform; Conn. mental health parity; Insurance premium increases in Iowa, Fla.

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News